Bacterial and Liposomal Antigen Processing
细菌和脂质体抗原处理
基本信息
- 批准号:7919824
- 负责人:
- 金额:$ 35.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-22 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimal ModelAntigen-Presenting CellsAntigensApoptosisApplications GrantsAutophagocytosisBiological ModelsCD8-Positive T-LymphocytesCD8B1 geneCell modelCellsContainmentCross PresentationCytosolDendritic CellsDetectionDevelopmentDiseaseDissectionFutureGenerationsGenesGrantHost DefenseHumanImmuneImmune responseImmunotherapyInfectionInterferon Type IIInterferonsKnockout MiceKnowledgeLeishmaniaLiposomesLungLymphoidMHC Class I GenesModelingMolecularMusMycobacterium InfectionsMycobacterium tuberculosisOrganOrganismOvalbuminPathogenesisPeptide HydrolasesPeptidesPhagosomesPlayProcessProductionReceptor SignalingRegulationResearchRespiratory physiologyRoleSalmonellaSiteSystemT-LymphocyteTestingToll-like receptorsToxoplasmaTuberculosisVaccine DesignVaccinesantigen processingcell typecytokinedesignfightinginterferon-alpha Blymph nodesmacrophagemeetingsmicrobicidemulticatalytic endopeptidase complexp97 ATPasepathogenpathogenic bacteriaresponse
项目摘要
DESCRIPTION (provided by applicant): Class I MHC Ag cross processing allows exogenous or vacuolar Ags to be processed for presentation to CD8+ T cells. Cross processing is essential for priming of CD8+ naive T cells by dendritic cells (DCs) in lymph nodes. A less recognized but potentially critical role of cross processing is to allow cells in non-lymphoid organs that are infected with vacuolar pathogens, e.g. Mycobacterium tuberculosis (MTB), to present pathogen-derived antigens to CD8+ effector T cells to elicit cytokine production or cytolytic function. DCs and macrophages may both harbor MTB and may hypothetically present MTB Ags to CD8+ effector T cells, allowing CD8+ T cells to contribute to containment of MTB infection. Research direction: This grant is to study basic mechanisms of bacterial Ag processing with a primary focus on MHC-I cross processing. MTB is selected as a model organism that represents an excellent model for processing of intravacuolar pathogens in addition to its significance as a human pathogen. Questions to be solved: We do not know which MTB-infected APCs have cross processing function; this has important implications for generation of immune responses vs. immune evasion. We do not understand mechanisms for cross processing of vacuolar pathogens, e.g. MTB, and cross processing functions of physiologically important lung APCs have not been investigated. Hypothesis: Cross processing of vacuolar organisms (e.g. MTB) allows recognition of infected cells by CD8+ T cells, contributing to host defense. DCs and macrophages may both cross present Ags to effector T cells, although they may use different cross processing mechanisms, undergo different regulation by pathogens, and play different roles in immune responses. Aim 1 addresses basic mechanisms of cross processing of MTB. Aim 2 investigates the cross processing functions of lung APCs. Aim 3 addresses regulation of cross processing by Toll-like receptors, interferons and MTB. Significance in lay terms: These studies will discover mechanisms that allow immune recognition of the causative agent of tuberculosis by CD8+ T cells, which help fight tuberculosis infection. This will increase our understanding of tuberculosis pathogenesis and aid development of strategies for enhanced vaccine design or immunotherapy for tuberculosis and other diseases.
描述(由申请人提供):I类MHC抗原交叉加工允许外源性或液泡抗原被加工以提呈给CD 8 + T细胞。交叉处理对于淋巴结中树突状细胞(DC)引发CD 8+初始T细胞是必不可少的。交叉处理的一个不太被认识到但可能至关重要的作用是允许被空泡病原体(例如结核分枝杆菌(MTB))感染的非淋巴器官中的细胞将病原体衍生的抗原呈递给CD 8+效应T细胞以引发细胞因子产生或细胞溶解功能。DC和巨噬细胞都可以携带MTB,并且可以假设将MTB Ag呈递给CD 8+效应T细胞,从而允许CD 8 + T细胞有助于遏制MTB感染。研究方向:该基金将研究细菌Ag加工的基本机制,主要关注MHC-I交叉加工。选择MTB作为模式生物,其除了作为人类病原体的重要性之外,还代表了用于处理液泡内病原体的优良模型。待解决的问题:我们不知道哪些MTB感染的APC具有交叉处理功能;这对免疫应答的产生与免疫逃避具有重要意义。我们不了解空泡病原体(例如MTB)的交叉处理机制,并且尚未研究生理学上重要的肺APC的交叉处理功能。假设:液泡生物(例如MTB)的交叉加工允许CD 8 + T细胞识别受感染的细胞,有助于宿主防御。DC和巨噬细胞都可以交叉提呈Ags给效应T细胞,尽管它们可能使用不同的交叉处理机制,受到病原体的不同调节,并且在免疫应答中发挥不同的作用。目标1阐述了结核分枝杆菌交叉加工的基本机制。目的2研究肺APC的交叉处理功能。目的3解决了Toll样受体、干扰素和MTB对交叉处理的调节。通俗意义:这些研究将发现允许CD 8 + T细胞免疫识别结核病病原体的机制,这有助于对抗结核病感染。这将增加我们对结核病发病机制的理解,并有助于制定针对结核病和其他疾病的增强疫苗设计或免疫疗法的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Clifford V Harding其他文献
CCAAT/Enhancer-Binding Protein β and δ Binding to CIITA Promoters Is Associated with the Inhibition of CIITA Expression in Response to Mycobacterium tuberculosis 19-kDa Lipoprotein1
CCAAT/增强子结合蛋白 β 和 δ 与 CIITA 启动子的结合与结核分枝杆菌 19-kDa 脂蛋白反应中 CIITA 表达的抑制相关
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:4.4
- 作者:
Meghan E. Pennini;Y. Liu;Jianqi Yang;C. Croniger;W. Boom;Clifford V Harding - 通讯作者:
Clifford V Harding
Clifford V Harding的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Clifford V Harding', 18)}}的其他基金
M. tuberculosis lipoprotein-TLR2 interactions
结核分枝杆菌脂蛋白-TLR2 相互作用
- 批准号:
7994850 - 财政年份:2006
- 资助金额:
$ 35.48万 - 项目类别:
M. tuberculosis lipoprotein-TLR2 interactions
结核分枝杆菌脂蛋白-TLR2 相互作用
- 批准号:
7739472 - 财政年份:2006
- 资助金额:
$ 35.48万 - 项目类别:
M. tuberculosis lipoprotein-TLR2 interactions
结核分枝杆菌脂蛋白-TLR2 相互作用
- 批准号:
7329170 - 财政年份:2006
- 资助金额:
$ 35.48万 - 项目类别:
M. tuberculosis lipoprotein-TLR2 interactions
结核分枝杆菌脂蛋白-TLR2 相互作用
- 批准号:
7535217 - 财政年份:2006
- 资助金额:
$ 35.48万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 35.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists